<DOC>
	<DOCNO>NCT01051466</DOCNO>
	<brief_summary>Previous research study show depression associate change structure activity different part brain antidepressant medication affect brain activity different part brain individual suffer depression . The primary purpose study find antidepressant medication duloxetine affect brain activity structure individual depression .</brief_summary>
	<brief_title>A Study Neurobiology Depression</brief_title>
	<detailed_description>This study evaluate participant depression treatment initiate treatment , compare control group healthy participant . The aim well understand neurobiology depression neurobiology change response treatment depression outcome treatment . The study include variety assessment neurobiology depression include : scan brain area involve depression look structure brain work blood test change relation several measure depression severity .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Major Depressive Disorder ( MDD ) participant : Are righthanded Meet criterion single episode recurrent MDD , without psychotic feature , define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) confirm Structured Clinical Interview DSMIVTR ( SCIDIV ) , without comorbid DSMIV Axis I II disorder screen Be free current antidepressant medication minimum 6 week fluoxetine treatment 4 week antidepressant treatment Have 17item Hamilton Depression Rating Scale ( HAMD17 ) total score â‰¥18 screening , baseline Women childbearing potential must negative urine pregnancy test prior enrollment agree use reliable method birth control study Healthy Participants Are righthanded Have HAMD17 total score &lt; 7 screen baseline must meet criterion MDD base SCIDIV MDD participant healthy participant : Are currently enrol , discontinue within last 30 day , clinical trial involve offlabel use investigational drug device Treatment within last 30 day drug receive regulatory approval Have previously complete withdrawn study study investigate duloxetine Have history substance abuse dependence within past 6 month A positive urine drug screen substance abuse dependence Have current DSMIVTR comorbid Axis I II disorder determine participant 's history investigator assessment Have history bipolar disorder , primary psychotic disorder ( schizophrenia , schizophreniform disorder , schizoaffective disorder , delusional disorder ) , know Alzheimer 's disease mental retardation , obsessivecompulsive disorder determine participant 's history investigator assessment Pregnant woman , woman breastfeed , woman childbearing potential use medically accept mean contraception engage sexual intercourse surgically sterilize Are judged investigator serious suicidal risk risk selfharm Have history recurrent selfmutilation selfharm Have uncontrolled narrowangle glaucoma Have diagnose acute liver injury ( hepatitis ) severe cirrhosis ( ChildPugh Class C ) Have endstage renal disease , prior renal transplant , current renal dialysis , severe renal impairment Have abnormal thyroidstimulating hormone ( TSH ) concentration Have electroconvulsive therapy ( ECT ) , transcranial magnetic stimulation ( TMS ) , vagus nerve stimulation ( VNS ) within past year Initiating psychotherapy within 6 week prior study entry study participation , stop , change psychotherapy study entry Have frequent and/or severe allergic reaction multiple medication , know allergic reaction study medication Known hypersensitivity duloxetine inactive ingredient Lack response current episode two adequate course antidepressant therapy clinically appropriate dose minimum 4 week judgment investigator participant meet criteria treatmentresistant depression Known human immunodeficiency virus ( HIV ) medical disorder know affect central nervous system ( CNS ) structure function assess investigator ( example , CNS neoplasms , neurosyphilis ) Have medical illness , clinically significant laboratory abnormality , take CNS active medication , opinion investigator , might interfere study participation ( example , likely require hospitalization ) , opinion investigator , might interfere interpretation primary endpoint ( example , hypertension diabetes ) Are unwilling unable comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>